ESR2 polymorphisms on prostate cancer risk: A systematic review and meta-analysis Article Swipe
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-1824385/v1
· OA: W4288039339
<title>Abstract</title> Purpose This meta-analysis was performed to address the association of two <italic>ESR2</italic> gene polymorphisms (rs1256049 and rs4986938) with susceptibility to cancer. Methods Extensive literature retrieve for eligible candidate gene studies published before May 10, 2022 was conducted in the PubMed, Medline and Web of Science. The search strategy is as follows: (ESR2 OR ERβ OR ER beta OR estrogen receptor beta) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (PCa OR PC OR prostate cancer). Potential sources of heterogeneity were sought out via trial sequential analysis, subgroup and sensitivity analysis. Results Overall, a total of 10 articles involving 18,064 cases and 19,556 controls for two polymorphisms of <italic>ESR2</italic> gene were enrolled. In the stratified analysis of rs1256049, we found that Caucasians might be correlated with an increased risk of prostate cancer, while less susceptibility was found in Asians. We observed that rs4986938 was not associated with prostate cancer risk. Conclusion <italic>ESR2</italic> rs1256049 polymorphism is associated with a higher risk of prostate cancer in Caucasian population and a lower risk of prostate cancer in Asian population.
